Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 4/20 | 0.71 |
| ▸ | CLK2 | P49760 | 3/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.71 |
| ▸ | GAK | O14976 | 1/20 | 0.71 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.71 |
| ▸ | JAK2 | O60674 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.71 |
| ▸ | NQO2 | P16083 | 1/20 | 0.71 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.71 |
| ▸ | FECH | P22830 | 1/20 | 0.71 |
| ▸ | JAK1 | P23458 | 1/20 | 0.71 |
| ▸ | TYK2 | P29597 | 1/20 | 0.71 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.71 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.71 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.71 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.71 |
| ▸ | CLK1 | P49759 | 1/20 | 0.71 |
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | JAK3 | P52333 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604747 | 0.87 | CLK2 (0.67) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| SCHEMBL5373329 | 0.86 | CLK2 (0.68) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| SCHEMBL5375708 | 0.86 | GAK (0.62) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| SCHEMBL7532858 | 0.83 | MAPK8 (0.71) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| SCHEMBL5380905 | 0.83 | MAPK8 (0.71) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| Cc-401 SCHEMBL4604749 | 0.83 | CLK2 (1.00) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| SCHEMBL8253744 | 0.83 | CLK2 (1.00) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| Cc-401 SCHEMBL30290855 | 0.83 | CLK2 (1.00) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| Cc-401 SCHEMBL23924447 | 0.82 | CLK2 (0.98) | MAPK8CLK2DYRK1AGAKDYRK3 | |
| Cc-401 SCHEMBL30198024 | 0.82 | CLK2 (0.98) | MAPK8CLK2DYRK1AGAKDYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220771-B2 | Methods of using indazole derivatives as JNK inhibitors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-22 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208513-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-04-24 | — | — | US | disclosed |
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| EP-1395363-A2 | ONE-STEP PRODUCTION OF 1,3-PROPANEDIOL FROM ETHYLENE OXIDE AND SYNGAS WITH A CATALYST WITH A N-HETEROCYCLIC LIGAND | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2004-03-10 | — | — | EP | disclosed |
| US-20030204118-A1 | One-step production of 1,3-propanediol from ethylene oxide and syngas with a catalyst with a N-heterocyclic ligand | KNIFTON JOHN FREDERICK (US) | 2003-10-30 | — | — | US | disclosed |
| US-6586643-B2 | Heating under pressure mixture of ethylene oxide, carbon monoxide, hydrogen, inert reaction solvent, and catalyst composition comprising non-ligated cobalt carbonyl compound and N-heterocyclic-ligated ruthenium carbonyl compound | SHELL OIL COMPANY | 2003-07-01 | — | — | US | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030060668-A1 | One-step production of 1, 3-propanediol from ethylene oxide and syngas with a catalyst with a N-heterocyclic ligand | SHELL OIL COMPANY | 2003-03-27 | — | — | US | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002094425-A2 | ONE-STEP PRODUCTION OF 1,3-PROPANEDIOL FROM ETHYLENE OXIDE AND SYNGAS WITH A CATALYST WITH A N-HETEROCYCLIC LIGAND | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2002-11-28 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077877-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPK8 25/4885CLK2 322/4885DYRK1A 784/4885 |
| US-20030060668-A1 | One-step production of 1, 3-propanediol from ethylene oxide and syngas with a catalyst with a N-heterocyclic ligand | SCO2, CYP2U1, CORO1A | MAPK8 3497/4885CLK2 807/4885DYRK1A 221/4885 |
| US-20030204118-A1 | One-step production of 1,3-propanediol from ethylene oxide and syngas with a catalyst with a N-heterocyclic ligand | SCO2, DUOX1, SYNGR2 | MAPK8 3237/4885CLK2 1776/4885DYRK1A 190/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPK8 25/4885CLK2 322/4885DYRK1A 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.